Navigation Links
Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer
Date:7/10/2020

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc.

“Dr. Nissenson is an industry leader and renowned authority on kidney disease,” said Sentien CEO, Brian Miller. “His executive experience will be critical for Sentien as we continue development of SBI-101 in patients with acute kidney injury and advance our novel cell therapy platform to treat other conditions characterized by systemic inflammation, including COVID-19.” “I’ve known Allen throughout his career and he is uniquely qualified to provide the clinical, policy and regulatory leadership that will guide Sentien through its next stage of growth,” added Sentien Executive Chairman, Rich Ganz. “He will be a valued addition to the executive team, and I look forward to the opportunity to work with him closely.”

“I am very excited to be joining Sentien Biotechnologies as Chief Medical Officer,” said Dr. Nissenson. “Sentien’s technology has the potential to transform the treatment of kidney disease as well as that of other systemic inflammatory conditions. I look forward to leading the clinical development efforts to bring this innovative treatment to patients with currently few therapeutic options.”

In addition to his current roles, Dr. Nissenson is the immediate past Chair of Kidney Care Partners, immediate past Co-Chair of the Kidney Care Quality Alliance, and he served as Director of the Dialysis Program and Associate Dean at the David Geffen School of Medicine at UCLA. He is a former President of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. Dr. Nissenson served for a year in Washington, D.C. as a Robert Wood Johnson Health Policy Fellow, working in the U.S. Senate with the late Senator Paul Wellstone. He earned his M.D. from Northwestern University Medical School.

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 allows for prolonged exposure of patient blood to the MSCs, resulting in the dynamic delivery of MSC-secreted factors at doses that are unattainable by direct injection.

SBI-101 is being evaluated in a Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An interim readout from the clinical study provides evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this therapeutic hypothesis, SBI-101 is being pursued in COVID-19 patients suffering from severe systemic inflammation.

Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective.

For more information, please visit http://www.sentienbiotech.com.

Read the full story at https://www.prweb.com/releases/sentien_biotechnologies_names_dr_allen_r_nissenson_as_chief_medical_officer/prweb17245085.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Sentien Biotechnologies Names Richard Ganz as Executive Chairman
2. Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
3. Portage Invests in Sentien Biotechnologies Inc.
4. Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines
5. Lifecycle Biotechnologies Announces Investment in a Biotechnology Campus in Cleburne, Texas
6. Lifecycle Biotechnologies Executes Exclusive Distribution Agreement with Midland Scientific
7. Lifecycle Biotechnologies Celebrates 20 Years of Business with Its Chata Biosystems Brand
8. Lifecycle Biotechnologies Names Aaron Schieving Vice President
9. B. Melina Cimler, PhD, Former Senior Vice President of Regulatory & Quality at Adaptive Biotechnologies, Joins NDA Partners
10. Lifecycle Biotechnologies Celebrates 40 Years of Business with its Boval BioSolutions Brand
11. Lifecycle Biotechnologies Announces Promotion of Ashley Wilhelm to Customer Outcomes Manager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2020)... ... August 11, 2020 , ... ... to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD ... 2022. The network is a consortium of academic research centers in the United ...
(Date:8/3/2020)... Ky. (PRWEB) , ... August 03, 2020 , ... Introducing ... products for transformative growth, , Known as MediVet Biologics since ... brand. , The new Ardent Animal Health will build on its base ...
(Date:7/31/2020)... Mass. and SOMERSET, N.J (PRWEB) , ... July ... ... leading genome editing company, and Catalent, the leading global provider of advanced delivery ... consumer health products, today announced that they have entered into a strategic partnership ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... After research ... The completion of a great surgery is only the beginning of a successful study, ... research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
Breaking Biology Technology:
(Date:7/22/2020)... Calif. (PRWEB) , ... July 21, 2020 , ... ... driving digital transformation and innovation in technology and compliance, announces a new solution ... device companies must ensure every layer of their technology stack complies with FDA ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • ... comparability study, but what is the most effective way to complete one? Will ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
Breaking Biology News(10 mins):